Leerink Partners is one of the most cited healthcare-investment-banking research desks on the peptide and obesity-drug story. Analyst Michael Cherny anchors the firm's Hims & Hers (NYSE: HIMS) coverage, with a Market Perform rating maintained through mid-2026. Cherny's June 27-28 weekend note framed the July 23-24 FDA Pharmacy Compounding Advisory Committee meeting as a 'modest binary event' for HIMS: an affirmative vote on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon opens real upside starting FY2027 (peptides as a new product category leveraging HIMS' California compounding facility acquired February 2025), while the procedural caveat is that PCAC votes have a mixed historical record and the FDA does not always follow committee recommendations.
The firm's broader peptide-class coverage spans the GLP-1 majors (Lilly, Novo Nordisk), telehealth platforms (HIMS, LifeMD, Henry Meds), and the compounding-pharmacy industry. Leerink's pre-PCAC framing sits alongside Barclays' June 17 PT raise to $39 (Overweight) and Canaccord Genuity's $32 Buy rating, defining a roughly $30-39 sell-side range that reflects the binary-event uncertainty heading into the July meeting.
Stories tagged here cover Leerink analyst notes, conference coverage, and the firm's healthcare investment-banking activity adjacent to peptide-class deal flow. See [[hims-hers]], [[pcac]], [[barclays]], and [[canaccord-genuity]] for adjacent threads.
Analyst coverage of Hims & Hers (NYSE: HIMS) ahead of the July 23-24 PCAC meeting consolidated through the weekend with two distinct framings. Leerink Partners' Michael Cherny called the PCAC vote a 'modest binary event,' acknowledging that an affirmative outcome on BPC-157, KPV, TB-500, MOTS-c, Emideltide/DSIP, Semax, or Epitalon would open real upside starting FY2027 and beyond (peptides as a large new product category for the company's owned California compounding facility), while flagging the procedural caveat that PCAC votes have a mixed record and the FDA does not always follow committee recommendations. Canaccord Genuity reiterated a 'Buy' rating on HIMS with a $32 price target framing peptides as part of the company's long-term preventive-health, longevity, and wellness portfolio expansion. The two analyst views sit alongside Barclays' June 17 PT raise to $39 (Overweight, weight-loss-momentum thesis). HIMS stock entered Monday June 29 up roughly 29.79% in June despite a 1.62% intraday decline, with the convergence of analyst price targets and the binary July 23-24 PCAC catalyst positioning the company as one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Hims & Hers Health (NYSE: HIMS) is up roughly 25% in June 2026 on multiple converging investor signals heading into the final week of the month. Novo Nordisk leadership called Hims one of its most 'voluminous' telehealth partners on a recent earnings call, validating the March 2026 branded-supply pact that ended the prior compounded-GLP-1 litigation. Leerink reiterated its Market Perform rating ahead of the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) meeting, framing peptides as the company's next major product category and a key 2027+ growth driver. Barclays raised its price target to $39 from $29 on June 17 with an Overweight rating. CEO Andrew Dudum confirmed Oura Ring integration is 'coming soon,' adding wearable connectivity to the platform. The Hims GLP-1 subscription stack now runs $39 for the first month and $149 monthly thereafter (excluding medication costs), with branded Novo Wegovy injections and pills available alongside the company's owned California compounding-pharmacy capacity for the post-PCAC peptide expansion. The convergence of investor signals (analyst PT raises, Novo validation, PCAC catalyst, wearable integration) makes HIMS one of the most-watched names in the obesity-and-longevity telehealth space heading into Q3 2026.
Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.
The Sunday coverage cycle on Lilly's Thursday TRIUMPH-1 readout settled into broadly favorable consensus. Leerink's David Risinger characterized the data as 'raising the bar for future novel obesity drug developers'; RBC Capital's Trung Huynh framed it as a 'clean win for Lilly'; Dan Skovronsky (Lilly CSO) called 30% weight loss 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' Mainstream press coverage — NPR, BioPharma Dive, CNBC, Good Morning America — uniformly led with the bariatric-surgery-territory framing (45.3% of 12 mg participants reaching ≥30% weight loss). The dysesthesia signal (12.5% at 12 mg) registered in pharma-industry coverage and analyst commentary but received minimal mainstream-press attention. The TRIUMPH-2 (obesity + T2D) and TRIUMPH-3 (obesity + CVD) readouts later in 2026 are the next inflection points; the NDA filing follows in Q4 2026 or Q1 2027.
Day-after analyst commentary on Lilly's Thursday TRIUMPH-1 topline split favorably across major sell-side and management voices. Leerink Partners' David Risinger wrote that 'tolerability and substantial weight loss shown by retatrutide is raising the bar for future novel obesity drug developers,' a framing that lands at the higher end of the analyst spectrum after William Blair's tolerability-confined assessment Thursday. RBC Capital Markets' Trung Huynh characterized the readout as a 'clean win for [Lilly]' citing the clean safety profile plus best-in-class efficacy across all three doses. Dan Skovronsky, Lilly's chief scientific and product officer, told CNBC over the weekend that 30% weight loss in the BMI ≥35 extension is 'an incredible number to see — we haven't seen that level of weight loss before with these kinds of medicines.' The Saturday-Sunday news-cycle handling has settled into broadly favorable territory.